BioPharma Resources

Investigational drug · Phase 2

VX-670

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Myotonic Dystrophy Type 1 (DM1).

Phase 2

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

2

Any phase or sponsor naming "VX-670"

First trial start

2024

Feb 20, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "VX-670", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Myotonic Dystrophy Type 1 (DM1)

Approved drugs for the same conditions: Rare and genetic disease

Largest trials

Live from ClinicalTrials.gov: studies naming "VX-670" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Myotonic Dystrophy Type 1 (DM1)

  • Del-desiranAOC 1001Phase 33 trials

    Avidity Biosciences, Inc. · DM1, Myotonic Dystrophy, Myotonic Dystrophy 1

  • zeleciment basivarsenDYNE-101Phase 32 trials

    Dyne Therapeutics · Myotonic Dystrophy Type 1 (DM1), DM1, Myotonic Dystrophy

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Vertex Pharmaceuticals.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.